1886-26-6

Usage

Uses

Used in Pharmaceutical Industry:
Norfenfluramine was used as an anorectic agent for the treatment of obesity. It was utilized for its ability to increase the release of serotonin in the brain, which helps regulate mood and appetite, thereby aiding in weight loss management.
However, due to the associated health risks and regulatory restrictions, Norfenfluramine is no longer used in the pharmaceutical industry for these purposes.

InChI:InChI=1/C10H12F3N/c1-7(14)5-8-3-2-4-9(6-8)10(11,12)13/h2-4,6-7H,5,14H2,1H3

Upstream product

• 783-04-0 2-Nitro-1-<3-trifluormethyl-phenyl>-propen-(1) 
• 454-89-7 3-Trifluoromethylbenzaldehyde 
• 135561-75-0 1-[(3′-trifluoromethyl)phenyl]-2-propanol 

Downstream Products

• 31173-14-5 N-<2-<1-methyl-2-(3-trifluoromethyl)phenyl>ethyl>aminoethanol 
• 22444-69-5 3-[1-Methyl-2-(3-trifluoromethyl-phenyl)-ethylamino]-propan-1-ol 
• 154140-26-8 <1-methyl-2-(3-phenyl)ethyl>phosphoramidate de diethyle 
• 29865-57-4 1-m-Trifluormethylphenyl-1-nitropropan 
• 52271-35-9 N-[1-Methyl-2-(3-trifluoromethyl-phenyl)-ethyl]-hydroxylamine 
• 73927-30-7 Acetic acid 2-[1-methyl-2-(3-trifluoromethyl-phenyl)-ethylamino]-ethyl ester 
• 73927-50-1 Propionic acid 2-[1-methyl-2-(3-trifluoromethyl-phenyl)-ethylamino]-ethyl ester 
• 73927-43-2 3-Methyl-but-2-enoic acid 2-[1-methyl-2-(3-trifluoromethyl-phenyl)-ethylamino]-ethyl ester 
• 73927-33-0 Chloro-acetic acid 2-[1-methyl-2-(3-trifluoromethyl-phenyl)-ethylamino]-ethyl ester 
• 73927-38-5 Cyclopropanecarboxylic acid 2-[1-methyl-2-(3-trifluoromethyl-phenyl)-ethylamino]-ethyl ester 
• 73927-51-2 4-Methyl-benzoic acid 2-[1-methyl-2-(3-trifluoromethyl-phenyl)-ethylamino]-ethyl ester 
• 73927-49-8 (E)-3-Phenyl-acrylic acid 2-[1-methyl-2-(3-trifluoromethyl-phenyl)-ethylamino]-ethyl ester 
• 73927-47-6 Phenyl-acetic acid 2-[1-methyl-2-(3-trifluoromethyl-phenyl)-ethylamino]-ethyl ester 
• 73927-32-9 4-Amino-benzoic acid 2-[1-methyl-2-(3-trifluoromethyl-phenyl)-ethylamino]-ethyl ester 

Relevant academic research and scientific papers

Hybrid Organo- and Biocatalytic Process for the Asymmetric Transformation of Alcohols into Amines in Aqueous Medium

A hybrid organo- and biocatalytic system for the asymmetric conversion of racemic alcohols into amines was developed. Combining an organocatalyst, AZADO, an oxidant, NaOCl, and an enzyme, ω-transaminase, we implemented a one-pot oxidation-transamination sequential process in aqueous medium. The method showed broad substrate scope and was successfully applied to conventional secondary alcohols and sterically hindered β-substituted cycloalkanols, where a highly stereoselective dynamic asymmetric bioamination enabled us to set up both contiguous stereocenters with very high enantio- and diastereomeric ratio (>90% yield, >99% ee, and up to 49:1 dr).

Phenylalkylamines and phenylalkylureas in combinations to suppress gastric bleeding in aspirin therapy

Novel pharmaceutical methods, combinations and compositions for reducing gastric bleeding during aspirin therapy for inflammation are disclosed. Compounds used in combination with aspirin are phenylalkylamines and phenylalkylureas having the formula: STR1 wherein Z is selected from the group consisting of --NHR2 or STR2 and R is selected from the group consisting of hydrogen, halogen, lower-alkoxy and trifluoromethyl and R1, R2, R3 and R4 are selected from the group consisting of hydrogen and lower-alkyl, where R3 and R4 taken together with the adjacent nitrogen atom may form a heterocyclic ring selected from the group of piperidino, pyrrolidino, piperazino, and morpholino.